Ocular Therapeutix (OCUL) Projected to Post Earnings on Monday

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Monday, May 5th. Analysts expect Ocular Therapeutix to post earnings of ($0.28) per share and revenue of $17.02 million for the quarter.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.05). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The company had revenue of $17.08 million for the quarter, compared to analyst estimates of $16.89 million. On average, analysts expect Ocular Therapeutix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Ocular Therapeutix Stock Up 3.2 %

Shares of OCUL traded up $0.27 during mid-day trading on Friday, hitting $8.80. 1,558,376 shares of the company's stock were exchanged, compared to its average volume of 1,449,511. Ocular Therapeutix has a twelve month low of $4.79 and a twelve month high of $11.78. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19. The firm has a fifty day moving average of $7.36 and a two-hundred day moving average of $8.44. The stock has a market cap of $1.40 billion, a price-to-earnings ratio of -6.67 and a beta of 1.49.

Analysts Set New Price Targets

Several analysts have recently weighed in on OCUL shares. JMP Securities set a $19.00 price objective on shares of Ocular Therapeutix in a report on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. Royal Bank of Canada initiated coverage on Ocular Therapeutix in a report on Tuesday, March 18th. They set an "outperform" rating and a $17.00 target price on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, April 8th. Finally, William Blair started coverage on shares of Ocular Therapeutix in a report on Tuesday, April 8th. They set an "outperform" rating for the company. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat, Ocular Therapeutix presently has a consensus rating of "Moderate Buy" and a consensus price target of $16.38.

Insider Activity

In other Ocular Therapeutix news, insider Donald Notman sold 11,119 shares of the company's stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $7.81, for a total transaction of $86,839.39. Following the transaction, the insider now owns 193,444 shares in the company, valued at approximately $1,510,797.64. This represents a 5.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Pravin Dugel sold 21,475 shares of the firm's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the completion of the sale, the insider now directly owns 3,520,318 shares in the company, valued at approximately $24,184,584.66. The trade was a 0.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 3.50% of the company's stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.